ProfileGDS5678 / 1423339_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 44% 43% 45% 43% 45% 45% 43% 43% 42% 41% 44% 41% 43% 43% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.0539444
GSM967853U87-EV human glioblastoma xenograft - Control 22.9858143
GSM967854U87-EV human glioblastoma xenograft - Control 33.0591545
GSM967855U87-EV human glioblastoma xenograft - Control 42.9432543
GSM967856U87-EV human glioblastoma xenograft - Control 53.0029845
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.1359445
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.050443
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.9873743
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.9577242
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.9217941
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.0228844
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.9015441
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.9984943
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.9968343